-
Leveling the Field: How the MFN Could Transform Drug Pricing
Sep 9, 2025, 16:22 PM -
Assessment Of Parental Knowledge Information-Seeking and Information-Providing Regarding Newborn And Infant Screening Examinations
Sep 9, 2025, 16:22 PM -
The Role of Environmental Evidence in HTA: Comparative Insights Into Global Assessment Frameworks
Sep 9, 2025, 16:22 PM -
AI Models for Predicting Clinical Trial Success: Capabilities and Risks of Pattern-Driven Approaches
Sep 9, 2025, 16:22 PM -
Cost per Responder Analysis of Teclistamab Compared to Real-World Physician’s Choice of Carfilzomib and/or Pomalidomide-Based Regimens for Triple-Class Exposed Patients With Refractory/Relapsed Multiple Myeloma
Sep 9, 2025, 16:22 PM -
Potential Impacts of Participating in an HIV Cure-Related Trial With an Analytical Treatment Interruption on Partners: Qualitative Research Findings
Sep 9, 2025, 16:22 PM -
Use of High-Cost Medicines in Secondary Care Settings in the English National Health Service
Sep 9, 2025, 16:22 PM -
Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study
Sep 9, 2025, 16:22 PM -
Comparing Countries’ Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States
Sep 9, 2025, 16:22 PM -
Impact of Nontransfusion-Dependent Thalassemia on Adult Patients' Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates
Sep 9, 2025, 16:22 PM -
The Burden of Patients With Severe Asthma: A Comparison Between Patients Treated With and Eligible for Monoclonal Antibodies Through a Retrospective Observational Analysis of Italian Real-World Data
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Rozanolixizumab for the Treatment of Generalized Myasthenia Gravis (gMG) in Greece
Sep 9, 2025, 16:22 PM -
Viable Rate of Return for Social Impact Bonds Supporting Research and Development of Gene Therapies for Rare Conditions
Sep 9, 2025, 16:22 PM -
Review of Rare Disease Policy Developments in Europe and Türkiye 2020-2025 in the Context of Innovative Orphan Drugs
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Standard-Dose vs. High-Dose Influenza Vaccination in Adults Aged ≥65 Years in Italy
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of TEVAR With Active Control in Patients With TAA and TBAD: A Japanese Public Healthcare Payer Perspective
Sep 9, 2025, 16:22 PM -
Impact of Different Thresholds of Increasing or Decreasing Body Mass Index on Noncommunicable Diseases Through a Discrete Event Simulation Model
Sep 9, 2025, 16:22 PM -
Real-World Insights From the LOGEX IMID Observatory: A Multicountry, Multiyear Analysis of Treatment Pathways and Healthcare Resource Utilization in Immune-Mediated Inflammatory Diseases
Sep 9, 2025, 16:22 PM -
How Health Policy Influences HTA Outcomes: Comparative Insights From Ukraine, Moldova, and Bulgaria
Sep 9, 2025, 16:22 PM -
Clinical Effectiveness and Safety of Second-Line Therapies for Immune Thrombocytopenia (ITP): A Systematic Literature Review
Sep 9, 2025, 16:22 PM
